Holen Sie sich die Stockscreener-App
0.5905
5.46%
-0.0341
Handel nachbörslich:
.60
0.0095
+1.61%
Schlusskurs vom Vortag:
$0.6246
Offen:
$0.6303
24-Stunden-Volumen:
585.52K
Relative Volume:
0.08
Marktkapitalisierung:
$35.14M
Einnahmen:
$950.10K
Nettoeinkommen (Verlust:
$-16.69M
KGV:
-0.7114
EPS:
-0.83
Netto-Cashflow:
$-15.16M
1W Leistung:
+2.48%
1M Leistung:
-27.77%
6M Leistung:
-35.82%
1J Leistung:
-45.83%
1-Tages-Spanne:
$0.585
$0.6399
1-Wochen-Bereich:
$0.576
$0.6566
52-Wochen-Spanne:
$0.3067
$1.80
Femasys Inc Stock (FEMY) Company Profile
Firmenname
Femasys Inc
Sektor
Telefon
770-500-3910
Adresse
3950 JOHNS CREEK COURT, SUWANEE
Vergleichen Sie FEMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.5905 | 37.16M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
585.08 | 209.96B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
205.18 | 57.75B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.62 | 39.80B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
250.92 | 36.23B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
41.25 | 31.82B | 27.43B | 1.27B | 1.01B | 1.5829 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | Laidlaw | Buy |
Femasys Inc Aktie (FEMY) Neueste Nachrichten
Can Femasys Inc. stock rebound after recent weakness2025 Market Sentiment & Safe Investment Capital Preservation Plans - ulpravda.ru
How Femasys Inc. stock performs after earnings2025 Price Momentum & Weekly High Momentum Picks - ulpravda.ru
Jonathan Schechter buys PharmaCyte Biotech shares worth $48,232 By Investing.com - Investing.com Nigeria
How Femasys Inc. stock reacts to inflationary pressures2026 world cup usa national team group stage goalkeepers counter attacking expert forecast guide - ulpravda.ru
Earnings Beat: Will MARZ stock keep high P E multiples2025 Biggest Moves & Pattern Based Trade Signal System - moha.gov.vn
Femasys gains UK approval for women's health products - MSN
Market Leaders: How strong is Femasys Inc stock balance sheetQuarterly Earnings Summary & AI Forecast for Swing Trade Picks - moha.gov.vn
User | theeveningleader.comFemasys Inc.Common Stock (Nasdaq:FEMY) Stock Quote - FinancialContent
Femasys files for at-the-market offering of up to $9.8 million in common stock - Investing.com India
Femasys Launches At-the-Market Common Stock Offering - TipRanks
Femasys files for at-the-market offering of up to $9.8 million in common stock By Investing.com - Investing.com South Africa
Femasys Inc Files Prospectus for Stock Offering - TradingView — Track All Markets
Suwanee company Femasys Inc. gets FDA approval for diagnostic device - The Business Journals
Will Femasys Inc. stock maintain growth story2025 Market Sentiment & Target Return Focused Stock Picks - Улправда
Contemporary OB/GYN week in review: FemVue clearance, flibanserin approval, and more - Contemporary OB/GYN
Swing Trade: Why Femasys Inc. stock is a must watch in 20252025 Geopolitical Influence & Accurate Intraday Trading Signals - Улправда
What momentum indicators show for Femasys Inc. stockMarket Sentiment Review & Risk Managed Trade Strategies - Bölüm Sonu Canavarı
Why Femasys Inc. stock is rated strong buyJuly 2025 Momentum & Real-Time Volume Spike Alerts - Улправда
Femasys receives FDA clearance for FemVue Controlled diagnostic device By Investing.com - Investing.com Australia
How interest rate cuts could boost Femasys Inc. stockMarket Growth Review & Technical Entry and Exit Tips - Bölüm Sonu Canavarı
How strong is Femasys Inc. stock balance sheet2025 Trading Recap & Consistent Profit Focused Trading Strategies - DonanımHaber
Why Femasys Inc. stock is a must watch in 20252025 Market Sentiment & Growth Oriented Trade Recommendations - Улправда
What analyst consensus says on Femasys Inc. stockJuly 2025 Action & AI Powered Market Trend Analysis - DonanımHaber
Femasys Earnings Notes - Trefis
PharmaCyte Biotech (Nasdaq: PMCB) reports Q2 loss and details QCLS, Femasys deals - Stock Titan
Femasys Inc. Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - marketscreener.com
FDA clears FemVue Controlled for in-office tubal assessment - Contemporary OB/GYN
Femasys secures U.S. FDA clearance for next-generation Femvue diagnostic device - marketscreener.com
Femasys Gains FDA Clearance for FemVue Diagnostic Device - TipRanks
Femasys gains FDA clearance for FemVue diagnostic device - MSN
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - The Manila Times
Femasys Inc Secures FDA Clearance for FemVue Diagnostic Device - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) secures FDA clearance for next-generation FemVue diagnostic - Stock Titan
Femasys receives FDA clearance for FemVue Controlled diagnostic device - Investing.com
Femasys Inc. Receives FDA Clearance for Innovative FemVue Controlled Device to Enhance Fallopian Tube Evaluation and Workflow Efficiency - Quiver Quantitative
New device could make fallopian tube testing simpler for fertility care - Stock Titan
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
Femasys Secures Major Order for FemBloc Launch - MSN
Femasys Receives FDA Approval for FemBloc Trial - MSN
FDA Approves Final Trial Phase for Femasys’ Permanent Birth Control Product - Medical Product Outsourcing
PharmaCyte’s Successful Stake Earns them Millions - StocksToTrade
PharmaCyte Boosts Financial Position with Femasys Stake Sale - timothysykes.com
Femasys Inc Stock Analysis and ForecastTechnical Breakout Signals & Minimal Capital Trading - earlytimes.in
CapEx per share of Femasys Inc. – NASDAQ:FEMY - TradingView
Femasys (NASDAQ:FEMY) Rating Increased to Hold at Wall Street Zen - MarketBeat
PharmaCyte Biotech stock surges following profitable exit from Femasys investment - MSN
Energy Moves: Why Femasys Inc. stock is a must watch in 2025Weekly Investment Report & Community Verified Trade Alerts - moha.gov.vn
Finanzdaten der Femasys Inc-Aktie (FEMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.26%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):